We rank companies based on fund manager, research analyst and news sentiment
AIMD stock icon



About: Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form.

Employees: 46

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

0.18% less ownership

Funds ownership: 0.55% [Q3] → 0.37% (-0.18%) [Q4]

44% less funds holding

Funds holding: 9 [Q3] → 5 (-4) [Q4]

49% less capital invested

Capital invested by funds: $69K [Q3] → $35.3K (-$33.7K) [Q4]

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Research analyst outlook

We haven’t received any recent analyst ratings for AIMD.

Financial journalist opinion